Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$432,500
-$1,270,000 QoQ
Shares Held
250,000
0.0% QoQ
Ownership
0.373%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#27
of 60 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Woodline Partners LP holds $4,400,572,274 across 197 Biotechnology names. ENGN ranks #186 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
2,002,863 | $375,096,182 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
1,414,173 | $173,349,326 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
4,000,567 | $125,057,724 | |
| 4 | BHVN |
Biohaven Ltd.
|
7,660,280 | $113,984,966 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
2,603,162 | $100,742,369 | |
| 6 | CYTK |
Cytokinetics Inc
|
1,100,708 | $93,769,314 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
3,007,798 | $92,730,412 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
2,500,673 | $88,498,817 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $432,500 | 250,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,702,500 | 250,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,257,500 | 250,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||